Home > News


Bankers pin Brazil energy recovery hopes on buyout firms, valuations
(Reuters) - Bankers dismayed by the small number of merger-and-acquisition closings in Brazil this year expect a turnaround, citing a weak local currency, cheaper assets and cash-flush buyout firms.

Dozens of deals stalled in the first six months of the year because of mounting economic and political turmoil. Still, advisory work remained rather intense in the period, forcing banks to deploy more staff than usual to handle otherwise normal transactions, bankers told Reuters on Wednesday.

Despite the still-murky outlook, government efforts to stabilize Latin America's largest economy are slowly reigniting investor confidence, bankers said. That, coupled with more attractive prices for takeover targets, should help transform their backlog of work into deal announcements.

"We already knew that this year wouldn't bring about any easy deals," said Alessandro Farkuh, head of M&A at Bradesco BBI. "Even with the outlook gradually improving, they're taking longer to close; we're spending more time and energy doing so."

In the year through June 30, companies announced $14.47 billion worth of M&A transactions in Brazil, the lowest in a decade, a Thomson Reuters deal intelligence report showed. The value of deals sank 39 percent from a year earlier, and 65 percent from the last six months of 2014.

Only 117 deals, worth $5.95 billion, were announced during the second quarter, as fallout from the nation's worst downturn in two decades and a graft scandal afflicting state-controlled oil producer Petróleo Brasileiro SA weighed on sentiment. That total was down from 139 deals announced in the first quarter, valued at about $8.5 billion.

Grupo BTG Pactual SA topped deal value rankings, after working on $7.53 billion worth of transactions in the period. Itaú BBA, the investment-banking unit of Itaú Unibanco Holding SA, topped the number of deal rankings with 17 transactions in the first six months.


The allure of cheaper takeover targets will soon begin to outweigh risks for some buyers as the gap between bids and asking prices narrows, said Rodrigo Mello, managing director with Greenhill & Co in Brazil. Price convergence should take place as a declining Brazilian currency helps trim the value of local assets in U.S. dollar terms, he said.

Multinational companies and other strategic players are brushing caution aside and seeking greater exposure to Brazil, some in search of a specific asset, others to tap the country's need for infrastructure.
Simplesa® recently published a paper by Dr. Autumn Frandsen, a Naturopathic Physician on their website that illustrates with supporting medical and research data that the combination of Arginine Alpha-Ketoglutarate, GABA, Ubiquinol and Niacin found in Simplesa AAKG+ Core Powder, along with Liposomal Glutathione, may enhance mitochondrial function and be effective stand alone and co-therapies in the management of Parkinson’s disease.
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1% of the population older than 50 years. There is a worldwide increase in disease prevalence due to the increasing age of human populations (1). PD is an idiopathic disease of the nervous system characterized by both motor and non-motor system manifestations. It is a chronic progressive neurodegenerative disorder that occurs mostly in older persons but can also appear in much younger patients. Other neurodegenerative disorders can mimic idiopathic PD, including Dementia with Lewy Bodies (DLB), Corticobasal Degeneration (CBD), Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). However, the major focus of the review was idiopathic (unknown cause) PD and not these other Parkinsonian-like syndromes (2).
Studies indicate that alternative and adjuvant therapies are promising and effective as co-therapies in the management of Parkinson’s disease. Simplesa AAKG+ Core Powder helps protect against mitochondrial dysfunction and neurogenic dysfunction. The combination of ingredients has been shown to exhibit benefits in several disease processes resulting from reduced cellular mitochondrial energy production. Its unique blend of Arginine Alpha-Ketoglutarate, GABA, Ubiquinol and Niacin provide support for hypertonic muscles, resulting in reduction of muscle fasciculations, leg cramps, muscular fatigue, fibromyalgia, and other muscular benefits. Arginine AKG helps synthesize nitric oxide which activates GABA recepxors, allowing for increased therapeutic effect in neurogenic disorders. Niacin and Ubiquinol have combined cardio-protective properties. Niacin lowers LDL and raises HDL, while Ubiquinol is the most bioavailable form of CoQ10, the primary energy source for cardiac cells. The synergistic combination of the four ingredients helps increase ATP production, making it therapeutically relevant in the support of depression, while also reducing exercise recovery time and the undesirable effects of aging. Anecdotal evidence and research indicates that these core nutrients also can be effective in management of Parkinson’s disease sympxoms and disease. GABA also exhibits anti-aging properties and may lower the incidence of Alzheimer’s disease and depression through its action on brain derived neurotrophic factor expression. 
    Opximizes mitochondrial function through a synergistic effect of its four ingredients.
    Restores cellular energy and drastically reduces muscle pain and weakness.
    Enhances cardiovascular and nervous system health by replacing necessary nutrients lost in the aging process.
    Increases mitochondrial energy production, reducing fatigue and recovery time post workout.

Previous :New design for CAIR pool series recuperator air

Next : A recuperator heat exchanger inside the engine can recovers waste heat from the exhaust